Methods and compositions for the sustained release of chromium

• US 9,675,702 B2
• Filed: 07/21/2015
• Issued: 06/13/2017
• Est. Priority Date: 03/13/2007
• Status: Active Grant

• Current Assignee: Nutrition21 LLC
• Original Assignee: JDS Therapeutics LLC
• Inventors: Komorowski, James R.
• Primary Examiner(s): STANFIELD, CHERIE MICHELLE
• Application Number:
  US14/805,136
• Publication Number:
  US 20150320796A1
• Time in Patent Office: 693 Days
• CPC Class Codes: A23L 33/165 Complexes or chelates
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A23V 2250/1586 Chromium
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/28 Compounds containing heavy metals
• CPC Class Codes: A61K 31/4172 Imidazole-alkanecarboxylic acids, e.g. histidine
• CPC Class Codes: A61K 31/4402 only substituted in position 2, e.g. pheniramine, bisacodyl
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61K 33/24 Heavy metals; Compounds thereof
• CPC Class Codes: A61K 47/545 Heterocyclic compounds A61K47/558 takes precedence
• CPC Class Codes: A61K 47/547 Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 3/08 for glucose homeostasis pancreatic hormones A61P5/48
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 5/50 for increasing or potentiating the activity of insulin
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

Provided herein are compositions for the administration of chromium that include at least two components: a hydrophilic chromium complex and a lipophilic chromium complex, and methods of using the same. Also provided are compositions for the administration of chromium that include a first “fast-acting” chromium complex and a second “slow-acting” chromium complex, wherein the first chromium complex is absorbed more quickly than the slow-acting chromium complex, and methods of using the same. Also provided herein are methods for treating, preventing, and improving conditions associated with cardiometabolic syndrome, by identifying a subject in need of treatment, prevention, or improvement of a condition associated with cardiometabolic syndrome, and providing a therapeutically effective amount of a composition comprising a fast-acting chromium complex and a slow-acting chromium complex, to the individual.

Claims

1. A composition comprising:

a first amount of chromium histidinate; and

a second amount of chromium picolinate;

wherein the first and second amounts have a molar ratio of chromium between 1;

10 and 10;

1.

2. The composition of claim 1, wherein the first amount and second amounts have a molar ratio of chromium between 1:

8 and 8;

1.

3. The composition of claim 1, wherein the first amount and second amounts have a molar ratio of chromium between 1:

4 and 4;

1.

4. The composition of claim 1, wherein the first amount and second amounts have a molar ratio of chromium between 1:

2 and 2;

1.

5. The composition of claim 1, wherein the first amount and second amounts have a molar ratio of chromium of about 1:

1.

6. The composition of claim 1, wherein first amount of chromium histidinate is selected from the group consisting of chromium and histidine, a chromium histidinate complex, and combinations thereof.

7. The composition of claim 1, wherein first amount of chromium histidinate consists essentially of a chromium histidinate complex.